AR031461A1 - FORMULACION FARMACEUTICA PARA ADMINISTRACION ORAL CON PROPIEDADES DE LIBERACION PROLONGADA, QUE COMPRENDE GEPIRONA CLORHIDRATO, UNA MATRIZ DE POLíMERO CELULoSICO Y UNA CELULOSA MICROCRISTALINA - Google Patents

FORMULACION FARMACEUTICA PARA ADMINISTRACION ORAL CON PROPIEDADES DE LIBERACION PROLONGADA, QUE COMPRENDE GEPIRONA CLORHIDRATO, UNA MATRIZ DE POLíMERO CELULoSICO Y UNA CELULOSA MICROCRISTALINA

Info

Publication number
AR031461A1
AR031461A1 ARP010105683A ARP010105683A AR031461A1 AR 031461 A1 AR031461 A1 AR 031461A1 AR P010105683 A ARP010105683 A AR P010105683A AR P010105683 A ARP010105683 A AR P010105683A AR 031461 A1 AR031461 A1 AR 031461A1
Authority
AR
Argentina
Prior art keywords
polymer matrix
amount
prolonged release
microcrystalline cellulose
oral administration
Prior art date
Application number
ARP010105683A
Other languages
English (en)
Spanish (es)
Inventor
Johannes Gerardus Jos Egberink
John Francis Engelhart
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of AR031461A1 publication Critical patent/AR031461A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP010105683A 2000-12-08 2001-12-07 FORMULACION FARMACEUTICA PARA ADMINISTRACION ORAL CON PROPIEDADES DE LIBERACION PROLONGADA, QUE COMPRENDE GEPIRONA CLORHIDRATO, UNA MATRIZ DE POLíMERO CELULoSICO Y UNA CELULOSA MICROCRISTALINA AR031461A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00204388 2000-12-08

Publications (1)

Publication Number Publication Date
AR031461A1 true AR031461A1 (es) 2003-09-24

Family

ID=8172397

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105683A AR031461A1 (es) 2000-12-08 2001-12-07 FORMULACION FARMACEUTICA PARA ADMINISTRACION ORAL CON PROPIEDADES DE LIBERACION PROLONGADA, QUE COMPRENDE GEPIRONA CLORHIDRATO, UNA MATRIZ DE POLíMERO CELULoSICO Y UNA CELULOSA MICROCRISTALINA

Country Status (19)

Country Link
EP (1) EP1343504A2 (cs)
JP (1) JP2004517083A (cs)
KR (1) KR20040018314A (cs)
CN (1) CN1479620A (cs)
AR (1) AR031461A1 (cs)
AU (1) AU2002226371A1 (cs)
BR (1) BR0115976A (cs)
CA (1) CA2436692A1 (cs)
CZ (1) CZ20031589A3 (cs)
EC (1) ECSP034627A (cs)
HU (1) HUP0401021A2 (cs)
IL (1) IL155855A0 (cs)
MX (1) MXPA03005099A (cs)
NO (1) NO20032581D0 (cs)
PL (1) PL362445A1 (cs)
RU (1) RU2003120446A (cs)
SK (1) SK6942003A3 (cs)
WO (1) WO2002045753A2 (cs)
ZA (1) ZA200303915B (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003274110A1 (en) * 2002-09-24 2004-04-19 Akzo Nobel N.V. Method to improve pharmaceutical tablets having a matrix of cellulose ether
BRPI0419179A (pt) * 2004-11-05 2007-12-18 Fabre Kramer Pharmaceuticals I formulação de alta dosagem de liberação prolongada de gepirona
EP3657966A1 (en) * 2017-07-26 2020-06-03 Abbott Laboratories Nutritional tablets and methods of making the same
CN109745323A (zh) * 2017-11-01 2019-05-14 四川科瑞德制药股份有限公司 氮哌酮类化合物提高副交感神经活性的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Also Published As

Publication number Publication date
IL155855A0 (en) 2003-12-23
CZ20031589A3 (cs) 2003-11-12
BR0115976A (pt) 2003-12-30
PL362445A1 (en) 2004-11-02
WO2002045753A3 (en) 2002-08-29
SK6942003A3 (en) 2003-10-07
CN1479620A (zh) 2004-03-03
ZA200303915B (en) 2004-08-20
JP2004517083A (ja) 2004-06-10
ECSP034627A (es) 2004-09-28
NO20032581L (no) 2003-06-06
MXPA03005099A (es) 2004-02-12
WO2002045753A2 (en) 2002-06-13
AU2002226371A1 (en) 2002-06-18
HUP0401021A2 (hu) 2004-09-28
KR20040018314A (ko) 2004-03-03
RU2003120446A (ru) 2005-02-20
EP1343504A2 (en) 2003-09-17
NO20032581D0 (no) 2003-06-06
CA2436692A1 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
AR062320A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
BRPI0518266B8 (pt) medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
AR022252A1 (es) Composicion de administracion oral.
AR032132A1 (es) Composicion farmaceutica que comprende una combinacion de un compuesto de tramadol y una droga anticonvulsiva y uso de la combinacion para preparar un medicamento
AR004391A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles.
BR0211198A (pt) Composições farmacêuticas e seu uso
KR960010007A (ko) 게피론 용량형
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
AR061166A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilferina
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
AP2003002763A0 (en) Controlled release formulations for oral administration
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
WO2002011694A3 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
AR031461A1 (es) FORMULACION FARMACEUTICA PARA ADMINISTRACION ORAL CON PROPIEDADES DE LIBERACION PROLONGADA, QUE COMPRENDE GEPIRONA CLORHIDRATO, UNA MATRIZ DE POLíMERO CELULoSICO Y UNA CELULOSA MICROCRISTALINA
BRPI0518741A2 (pt) uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
AP1485A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin.
HOUSE homes
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
PE20060124A1 (es) Tabletas de desintegracion que comprenden licarbazepina
DE69803670D1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal